Applying Liver MPS Technologies to Improve Preclinical DILI Prediction

• Demonstrate how liver microphysiological systems improve mechanistic understanding and human relevance in assessing drug‑induced liver injury
• Present case studies where liver MPS provide earlier or more predictive detection of hepatotoxic liabilities compared with traditional in vitro assays
• Highlight translational biomarkers and functional readouts from MPS that strengthen decision‑making in preclinical safety assessment

Speakers:

May Freag

Associate Scientific Director, Nonclinical Safety & Pharmacology

Takeda Pharmaceutical